Percheron Therapeutics (AU:PER)
ASX:PER
Want to see AU:PER full AI Analyst Report?
PER Stock Chart & Stats
AU$0.01
<AU$0.01(12.50%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(12.50%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume20.44M
Average Volume (3M)2.49M
Market Cap
AU$6.85M
Enterprise ValueAU$567.71K
Total Cash (Recent Filing)AU$4.46M
Total Debt (Recent Filing)AU$10.68K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,522,412,700
10 Day Avg. Volume2,742,659
30 Day Avg. Volume2,485,493
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$2.15M
Percheron Therapeutics News
PER FAQ
What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Percheron Therapeutics’s market cap?
Percheron Therapeutics’s market cap is AU$6.85M.
When is Percheron Therapeutics’s upcoming earnings report date?
Percheron Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 83 days.
How were Percheron Therapeutics’s earnings last quarter?
Percheron Therapeutics released its earnings results on Feb 26, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is Percheron Therapeutics overvalued?
According to Wall Street analysts Percheron Therapeutics’s price is currently Overvalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,522,412,700 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Percheron Therapeutics reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in AU:PER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PER Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$107.0K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-110.74%
Trailing 12-Months
Asset Growth
-52.52%
Trailing 12-Months
Company Description
Percheron Therapeutics
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
Technical Analysis
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Cronos Australia Ltd.
―
Options Prices
Currently, No data available
---